Why the study?
Should predicted lifetime as well as short-term cardiovascular disease risk inform who gets statins and when?
Should predicted lifetime as well as short-term cardiovascular disease risk inform who gets statins and when?
Short-term cardiovascular disease risk assessment remains the most useful tool for guiding statin therapy, though a trajectory predicting short-term risk over a lifetime may address current deficiencies.
Answers are grounded in this paper and cite their sources.
Short-term CVD risk guides statin decisions; lifetime risk leaves open its utility for identifying benefit.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Rod Jackson (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: